Trial Profile
A Single Arm, Open Label, Phase II Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 09 Aug 2023 Status changed from active, no longer recruiting to completed.
- 06 May 2023 Planned End Date changed from 1 Apr 2024 to 1 Jul 2023.
- 13 Dec 2022 Primary endpoint has been met (Proportion of patients with complete and partial responses in skin and/or joint), as per Results presented at the 64th American Society of Hematology Annual Meeting and Exposition